Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Background Patients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC,...

Olles dieđut

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkkit:	Mark Awad, Mizuki Nishino, Mehmet Altan, Biagio Ricciuti, Fangxin Hong, Matthew Hellmann, John V Heymach, Joao V Alessi, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMJ Publishing Group 2020-10-01
Ráidu:	Journal for ImmunoTherapy of Cancer
Liŋkkat:	https://jitc.bmj.com/content/8/2/e001007.full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Geahča maid